ClearB is working to develop therapeutic vaccines designed to redirect patients’ immune systems toward functional cure of hepatitis B.

The World Health Organisation defines hepatitis B as “a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.”

At ClearB, we are working to develop immunotherapies which harness the bodies’ natural immune system to result in a functional cure for chronic hepatitis B (CHB).

Approx. 2 billion people are infected with HBV and ~250 million living with chronic hepatitis B (CHB) virus infection
Viral hepatitis is the 7th ranked cause of human death
15-25% of people with CHB develop advanced liver disease &/or HCC (without appropriate clinical management)
Liver cancer is the 3rd most common cause of cancer death globally

News & Publications

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of preclinical chronic hepatitis B data at AASLD 2024.

ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2024

ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection